Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 29, 2025

Datavault AI Inc. Announces Board Approval of Dividend of Dream Bowl Meme Coin II to All Eligible Record Equity Holders of Datavault AI

View original at globenewswire.com
Datavault AI Inc. Announces Board Approval of Dividend of Dream Bowl Meme Coin II to All Eligible Record Equity Holders of Datavault AI PHILADELPHIA, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Datavault AI is building an AI-powered token designed with purpose, transparency, and long-term potential in mind

    80% confidence

  • The Dream Bowl Meme Coin II digital collectibles may not have or maintain any value

    80% confidence

  • Datavault AI remains committed to innovative stockholder value creation

    80% confidence

  • The payment date for the dividend will be within 60 days following the record date

    80% confidence

  • The Dream Bowl Meme Coin II does not represent or confer any equity, voting, dividend, profit-sharing, or ownership rights

    80% confidence

  • The Dream Bowl Meme Coin II is not designed or intended to function as an investment, currency, or financial product

    80% confidence

Data points we hold from this source

Datavault AI Inc. · dividend record date2026-01-07 date
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com